Indexed with PubMed and Science Citation Index (E) 
Users online: 1242 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
   Next article
   Previous article 
   Table of Contents
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (180 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded648    
    Comments [Add]    
    Cited by others 20    

Recommend this journal


Year : 2008  |  Volume : 74  |  Issue : 2  |  Page : 157-158

Omalizumab in severe chronic urticaria

Consultant Dermatologist, Mumbai, India

Correspondence Address:
K V Godse
Shree Skin Centre, 22, L market, Sector 8, Nerul, Navi Mumbai - 400 706
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0378-6323.39708

Rights and Permissions

How to cite this article:
Godse K V. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol 2008;74:157-8

How to cite this URL:
Godse K V. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol [serial online] 2008 [cited 2017 Nov 21];74:157-8. Available from: http://www.ijdvl.com/text.asp?2008/74/2/157/39708


Urticaria patients are usually treated with oral antihistamines and 50% of them respond well to this treatment. However, the other 50% do not respond to antihistamines and need a more aggressive approach. Approximately 40-50% of patients with no apparent cause for their urticaria are believed to have an associated autoimmune profile that may play a pathogenetic role. We describe here a patient who responded to omalizumab after failure to respond to cyclosporine.

A forty-five-year old female presented with severe chronic urticaria prevalent for the last ten years and which did not respond to antihistamines and steroids. About five years ago, the patient was diagnosed to have sarcoidosis and was treated with oral steroids. She had developed osteoporosis due to repeated courses of oral steroids in the past. She also had a history of bronchial asthma, which was controlled with a bronchodilator. She was started on cyclosporine at a dose of 3 mg/kg in December 2006. Her urticaria was well controlled with cyclosporine until June 2007. Later, her urticaria worsened in spite of regular doses of cyclosporine and antihistamines in combination (hydroxyzine 25 mg three times a day and fexofenadine 180 mg daily). Hence, the dose of cyclosporine was doubled to 6 mg/Kg per day (300 mg) but her urticaria was not controlled. The addition of montelukast also did not help.

Her blood investigations including complete blood counts, biochemistry and thyroid stimulating hormone (TSH) were within normal limits. Serum protein electrophoresis was normal. Autologous serum skin test could not be performed as antihistamines could be not stopped even for a single day. Serum immunoglobulin E (IgE) was 778 as against the normal level of 100. At this stage, she was started on omalizumab 300 mg every four weeks in consultation with a chest physician in addition to cyclosporine, antihistamines and montelukast. After the first injection, she showed more than 90% control of her urticaria, while after the second injection, she had total relief from her symptoms, which lasted for four weeks.

Omalizumab, a recombinant, humanized, monoclonal antibody against immunoglobulin IgE, represents a unique therapeutic approach for the treatment of allergic diseases. This agent acts as a neutralizing antibody by binding IgE at the same site on IgE as its high-affinity receptor, F cεR I . Subsequently, IgE is prevented from sensitizing cells bearing high-affinity F cεR I receptors. Inhibition of the biological effects of IgE targets an early phase of the allergic cascade before the generation of allergic symptoms. [1] Omalizumab reduces serum levels of IgE and blocks the attachment of IgE to mast cells and other immune cells, thereby preventing IgE-mediated inflammatory changes. Omalizumab is approved for the treatment of moderate-to-severe persistent asthma in adults and adolescents older than 12 years of age who have a positive skin test to a perennial allergen. [2] Dosing is based on weight and pretreatment serum IgE levels and is administered via subcutaneous injection every 2-4 weeks. The safety profile of omalizumab is favorable with injection site reaction being the most commonly reported adverse event.

There are reports of the efficacy of omalizumab in chronic urticaria [3] and atopic dermatitis. [4] The incidence of anaphylaxis in clinical trials for omalizumab was 0.1%. [5] Boyce describes a successful treatment of cold urticaria with omalizumab. [6] Anti-IgE treatment induces the depletion of free IgE from the serum and tissue, leading ultimately to reduced binding of IgE to its high-affinity surface receptor, F cεR I . As occupancy of F cεR I by IgE determines the levels of surface F cεR I expression, this leads to a rapid depletion of both cell-bound IgE and surface F cεR I expression on blood basophils.

Omalizumab may have a beneficial effect in the treatment of chronic urticaria. Further studies are needed to confirm this effect and better elucidate the mechanism for the observed improvement.

  References Top

1.Mankad VS. Omalizumab: Other indications and unanswered questions. Clin Rev Allergy Immunol 2005;29:17-30.  Back to cited text no. 1    
2.Graves JE, Nunley K, Heffernan MP. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab and alefacept. J Am Acad Dermatol 2007;56:e55-79.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99:190-3.  Back to cited text no. 3  [PUBMED]  
4.Forman SB, Garrett AB. Success of omalizumab as monotherapy in adult atopic dermatitis: Case report and discussion of the high-affinity immunoglobulin E receptor, Fcepsilon RI. Cutis. 2007;80:38-40.  Back to cited text no. 4    
5.Scheinfeld N. Omalizumab: A recombinant humanized monoclonal IgE-blocking antibody. Dermatol Online J 2005;11:2.  Back to cited text no. 5    
6.Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE J Allergy Clin Immunol 2006;117: 1415-8.  Back to cited text no. 6    

This article has been cited by
1 Omalizumab (Xolair) in Children above 12 Years With Chronic Urticaria: A Review of Literature
Javad Ghaffari,Soheila Shahmohammadi,Hossein Ashrafi,Ali Reza Ranjbar,Negar Ghaffari
Journal of Pediatrics Review. 2015; 3(1)
[Pubmed] | [DOI]
2 The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria
Tse Wen Chang,Christina Chen,Chien-Jen Lin,Martin Metz,Martin K. Church,Marcus Maurer
Journal of Allergy and Clinical Immunology. 2014;
[Pubmed] | [DOI]
3 Treatment of Refractory Chronic Urticaria: Current and Future Therapeutic Options
Riccardo Asero,Alberto Tedeschi,Massimo Cugno
American Journal of Clinical Dermatology. 2013;
[Pubmed] | [DOI]
4 Treatment of Chronic Urticaria
Riccardo Asero,Alberto Tedeschi,Massimo Cugno
Immunology and Allergy Clinics of North America. 2013;
[Pubmed] | [DOI]
5 Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis
Martin Metz,Tatevik Ohanyan,Martin K. Church,Marcus Maurer
Journal of Dermatological Science. 2013;
[Pubmed] | [DOI]
6 Diagnosis and Treatment of Urticaria and Angioedema
Mario Sánchez-Borges,Riccardo Asero,Ignacio J. Ansotegui,Ilaria Baiardini,Jonathan A Bernstein,G Walter Canonica,Richard Gower,David A Kahn,Allen P Kaplan,Connie Katelaris,Marcus Maurer,Hae Sim Park,Paul Potter,Sarbjit Saini,Paolo Tassinari,Alberto Tedeschi,Young Min Ye,Torsten Zuberbier
World Allergy Organization Journal. 2012; 5(11): 125
[Pubmed] | [DOI]
7 Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase
Journal of Allergy and Clinical Immunology. 2011;
[VIEW] | [DOI]
8 Consensus statement on the management of urticaria
Godse, K., Zawar, V., Krupashankar, D., Girdhar, M., Kandhari, S., Dhar, S., Ghosh, S., (...), Zuberbier, T.
Indian Journal of Dermatology. 2011; 56(5): 485-489
9 Immunological effects of omalizumab in chronic urticaria: A case report
Lemoli, E., Piconi, S., Fusi, A., Borgonovo, L., Borelli, M., Trabattoni, D.
Journal of Investigational Allergology and Clinical Immunology. 2010; 20(3): 252-254
10 Elevated serum total IgE - A potential marker for severe chronic urticaria
Kessel, A., Helou, W., Bamberger, E., Sabo, E., Nusem, D., Panassof, J., Toubi, E.
International Archives of Allergy and Immunology. 2010; 153(3): 288-293
11 Treatment of chronic urticaria
Tončić, R.J., Lipozenčić, J., Marinović, B.
Acta Dermatovenerologica Croatica. 2009; 17(4): 305-322
12 Monoclonal antibodies and other biologic agents in the treatment of asthma
Long, A.A.
mAbs. 2009; 1(3): 237-246
13 Prevalence and relevance of skin autoreactivity in chronic  urticaria
Karoline Krause,Martin Metz,Markus Magerl,Marcus Maurer
Expert Review of Dermatology. 2009; 4(6): 655
[Pubmed] | [DOI]
14 EAACI/GA˛LEN/EDF/WAO guideline: management of urticaria
T. Zuberbier,R. Asero,C. Bindslev-Jensen,G. Walter Canonica,M. K. Church,A. M. Giménez-Arnau,C. E. H. Grattan,A. Kapp,M. Maurer,H. F. Merk,B. Rogala,S. Saini,M. Sánchez-Borges,P. Schmid-Grendelmeier,H. Schünemann,P. Staubach,G. A. Vena,B. Wedi
Allergy. 2009; 64(10): 1427
[Pubmed] | [DOI]
15 Chronic urticaria and treatment options
Godse, K.V.
Indian Journal of Dermatology. 2009; 54(4): 310-312
16 Monoclonal antibodies and other biologic agents in the treatment of asthma
Aidan A. Long
mAbs. 2009; 1(3): 237
[Pubmed] | [DOI]
17 EAACI/GALEN/EDF/WAO guideline: Management of urticaria
Zuberbier, T., Asero, R., Bindslev-Jensen, C., Walter Canonica, G., Church, M.K., Giménez-Arnau, A.M., Grattan, C.E.H., (...), Wedi, B.
Allergy: European Journal of Allergy and Clinical Immunology. 2009; 64(10): 1427-1443
18 Biologics in dermatologic therapy - An update
Coondoo, A.
Indian Journal of Dermatology. 2009; 54(3): 211-220
19 Eosinophils in Chronic Urticaria: Supporting or Leading Actors?
Riccardo Asero,Massimo Cugno,Alberto Tedeschi
World Allergy Organization Journal. 2009; 2(9): 213
[Pubmed] | [DOI]
20 Prevalence and relevance of skin autoreactivity in chronic urticaria
Krause, K., Metz, M., Magerl, M., Maurer, M.
Expert Review of Dermatology. 2009; 4(6): 655-663


Print this article  Email this article
Previous article Next article


Online since 15th March '04
Published by Wolters Kluwer - Medknow